Titlebook: Resistance to Proteasome Inhibitors in Cancer; Molecular Mechanisms Q. Ping Dou Book 2014 Springer International Publishing Switzerland 201

HBA1C

書目名稱Resistance to Proteasome Inhibitors in Cancer影響因子(影響力)




書目名稱Resistance to Proteasome Inhibitors in Cancer影響因子(影響力)學(xué)科排名




書目名稱Resistance to Proteasome Inhibitors in Cancer網(wǎng)絡(luò)公開度




書目名稱Resistance to Proteasome Inhibitors in Cancer網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Resistance to Proteasome Inhibitors in Cancer被引頻次




書目名稱Resistance to Proteasome Inhibitors in Cancer被引頻次學(xué)科排名




書目名稱Resistance to Proteasome Inhibitors in Cancer年度引用




書目名稱Resistance to Proteasome Inhibitors in Cancer年度引用學(xué)科排名




書目名稱Resistance to Proteasome Inhibitors in Cancer讀者反饋




書目名稱Resistance to Proteasome Inhibitors in Cancer讀者反饋學(xué)科排名

Biomarker

Preclinical Studies on the Molecular Basis of Bortezomib Resistance and Modalities to Overcome Resiercome resistance, e.g., by novel proteasome inhibitors and combinations of bortezomib with other chemotherapeutic drugs. Finally, an update is provided of the ongoing clinical trials investigating the potential benefits of proteasome inhibitors in acute leukemia.

IRK

travail

Resistance to Proteasome Inhibitors in Multiple Myeloma, bone destruction, anemia, hypercalcemia, and renal failure. Although MM remains incurable, a dramatic paradigm shift in the treatment of MM has occurred over the past decade through the introduction of novel agents, including the development of small molecule inhibitors targeting the proteasome. Am

愉快嗎

Wordlist

多山

Recess

俗艷

alleviate

Overcoming Inherent Resistance to Proteasome Inhibitors in Head and Neck Cancer: Challenges and Newthe in vitro sensitivity of HNSCC cells to proteasome inhibitors, clinical testing of bortezomib in HNSCC patients has encountered obstacles of inherent resistance and adverse toxicities. To combat these difficulties, current efforts are focused on developing strategies that co-target the proteasome